Login to Your Account

In The Clinic NEWS
Regeneron Pharmaceuticals Inc. and Sanofi SA began dosing patients in the first of several planned phase III studies of the potential blockbuster dupilumab (REGN668/SAR231893).
When Celgene Corp. reported that it was shelling out a whopping $710 million up front to little known privately held Nogra Pharma Ltd. to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate to severe Crohn's disease (CD), eyebrows were raised by analysts who follow the company.
With encouraging data from a phase I trial in amyotrophic lateral sclerosis (ALS) and a phase II trial under way testing NSI-566, Neuralstem Inc. has begun – with the same candidate – the first human neural stem cell study to be given the FDA's nod for chronic spinal cord injury.
More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: